BlinkLab

BlinkLab AAQS

The The AAQS of BlinkLab (BB1.AX) as of Oct 27, 2026 is 2. In the previous year, The AAQS was 2.00 — a change of 0.00% (lower).

AAQS

2

YoY

0.00%

Last updated:

BlinkLab has a current AAQS of 2.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock BlinkLab in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

The BlinkLab AAQS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

AAQS
Date
AAQS
Jan 1, 2022
2.00 AUD
Jan 1, 2023
2.00 AUD
Jan 1, 2024
2.00 AUD
Jan 1, 2025
2.00 AUD
Jan 1, 2026
2.00 AUD
The BlinkLab AAQS history
YEARAAQSYoY
20.00%
20.00%
20.00%
20.00%
2—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BlinkLab Stock analysis

What does BlinkLab do? BlinkLab Ltd offers the BlinkLab Dx system, comprising the BlinkLab App and BlinkLab Portal, to conduct neurobehavioral tests for diagnosing neurological disorders. The BlinkLab App enables patients, caregivers, and parents to complete tests in real time, while the BlinkLab Portal provides secure database management, CMS, and tools for customizing neurometric tests, data analysis, and visualization. The company generates revenue through the sale of these products to healthcare providers, research institutions, and clinics seeking cost-effective diagnostic solutions for neurological and psychiatric conditions. The BlinkLab Tests, including eyeblink conditioning (EBC), prepulse inhibition of acoustic startle (PPI), and habituation of eye blink response, serve as biomarkers for such disorders, making the system valuable for early detection and monitoring. Healthcare providers, research institutions, and clinics purchase the BlinkLab Dx system to integrate objective neurobehavioral testing into their diagnostic workflows. The BlinkLab App collects real-time data from test subjects, and the BlinkLab Portal allows for comprehensive data management and analysis, supporting both clinical and research applications. The company’s focus on biomarkers like EBC, PPI, and habituation of eye blink response positions it as a key tool for diagnosing disorders such as schizophrenia, ADHD, and autism spectrum disorders, which are increasingly recognized in clinical practice. The BlinkLab Tests, including eyeblink conditioning (EBC), prepulse inhibition of acoustic startle (PPI), and habituation of eye blink response, are marketed as objective biomarkers for neurological and psychiatric disorders. By leveraging mobile technology, BlinkLab Ltd provides a cost-effective alternative to traditional diagnostic methods, appealing to institutions looking to streamline their diagnostic processes. The company’s revenue model relies on selling the BlinkLab App and Portal as integrated solutions, with no mention of additional services or third-party partnerships in the business description. BlinkLab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BlinkLab stock

The AAQS of BlinkLab is 2 in 2026.

On Eulerpool you can find the complete historical development of The AAQS BlinkLab since 2006 – with annual values, charts, and detailed analysis.

The AAQS is a key figure developed by AlleAktien.

The AAQS is a key figure developed by AlleAktien.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — BlinkLab

All Key Metrics — BlinkLab